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ABSTRACTS0329: PATIENT ACCESS TO IMMEDIATE BREAST RECONSTRUCTION
FOLLOWING CANCER SURGERY. LEARNING FROM THE NATIONAL MAS-
TECTOMY AND BREAST RECONSTRUCTION AUDIT (NMBRA)
Senthurun Mylvaganam, Niraj Vethirajan, Khalid Boussouara,
George Metaxas, Hemant Ingle. Good Hope Hospital, Heart of England NHS
Trust, Sutton Coldﬁeld, Birmingham, UK.
Introduction: NICE guidance requires breast reconstruction discussionwith
all patients requiring mastectomy. The national mastectomy and recon-
struction audit showed signiﬁcant variation in accessibility and practice
in NHS Trusts offering breast reconstruction. Our trust service has evolved
since the audit combining breast and dedicated plastic surgeons on site.
Aims: Assess current local accessibility and practice for offering immediate
breast reconstruction following mastectomy.
Methods: Retrospective analysis of patients undergoing mastectomy for
cancer at Heart of England NHS trust (HEFT) between September 2011 to
July 2012. Data collected on tumour biology, whether reconstruction op-
tions offered and if not performed why.
Results: N¼76. Mean Nottingham Prognostic Index(NPI)¼4.03. Mean
age¼61(31-90)
Immediate reconstruction offered ¼46%. Immediate reconstruction per-
formed ¼25%. Reconstruction techniques; immediate with expander(2),
immediate delayed with expander(5), Transverse Rectus Abdominis
Myocutaneous(TRAM) free ﬂap(7), Lattissimus Dorsi(LD) pedicled ﬂap(2),
LD with implant(2), Deep Inferior Epigastric Perforator(DIEP) free ﬂap(1).
Reasons reconstruction not performed; patient choice(8), patient choosing
delayed(6).
Conclusion: Our trust breast cancer service is a partnership between
breast and plastic surgeons with joint MDT and clinic services. The trust
rate of discussion of immediate reconstruction is greater than
the published NMBRA local cancer network rate(36%). An integrated
oncoplastic service is a key measure towards fulﬁlling NICE guidance.
0331: THE IMPORTANCE OF NEEDLE CORE BIOPSY IN THE DIAGNOSIS
OF PHYLLOIDES TUMOURS
Senthurun Mylvaganam1, Lucinda Frank 2, Clare Toro 1, Sarah Vestey 2,
Steven Thrush 1. 1Worcester Royal Hospital, Worcestershire Acute NHS Trust,
Worcester, Worcestershire, UK; 2Gloucestershire Hospitals NHS Trust,
Gloucester, Gloucestershire, UK.
Introduction: Phylloides tumours are rare ﬁbroepithelial breast tumours
and are usually clinically and radiological indistinguishable from ﬁbroa-
denomas. This makes core biopsy the main method of diagnosis. Only
small studies have looked at the diagnostic histological accuracy of needle
core biopsy(NCB) and none have addressedwhether there is any variability
of NCB accuracy between institutions.
Aims: To assess the diagnostic accuracy of NCB compared to the gold
standard excision biopsy report in 2 separate hospitals trusts.
Methods: Multicentre retrospective analysis of all cases of phylloides tu-
mours on core and/or excision biopsy from March 2006 to July 2012 at
Worcestershire Acute NHS Trust (WAHNST) and Gloucestershire hospitals
NHS Trust (GHNHST).
Results: N¼94. Mean age¼48. Mean clinical size¼31.7mm, mean radio-
logical size¼35.4mm. WAHNST n¼42. NCB Sensitivity¼87% and Positive
Predictive Value(PPV)¼90%. GHNHST n¼52 NCB Sensitivity¼74% and
PPV¼100%.
Conclusion: The high sensitivity of NCB shown demonstrates its impor-
tance in the diagnosis of Phylloides tumours (comparative study in liter-
ature 63%). There does appear to be variation between pathologists in
interpretation of NCB, which may be caused by the interpretation of the
criteria for diagnosing Phylloides. NCB is not 100% sensitive at diagnosing
these tumours so there must be local protocols to ensure tumours are not
missed.
0434: BREAST CANCER SURGERY IS SAFE IN THE ELDERLY PATIENT
Ramesh Yap Kannan, Nadi Khaldoun, Khawaja Saira, Sumrien Haytham,
Holt Simon, Sharaiha Yousef. Prince Philip Hospital, Llanelli,
Carmarthenshire, UK.
Aims: To assess the safety of surgical resection of breast cancer in patients
over 70 years
Methodology: A retrospective study of 188 consecutive patients diag-
nosed with breast cancer at the age of 70 or older (2004 to 2008). Noteswere examined for demographics, treatment, complications and ﬁnal
outcome. Patients received surgery with an intent to cure (SC) or conser-
vative treatment (C).
Results: 68 patients received C and 120 patients underwent SC. SC was
performed in 63.8%(120 of 188), of whom 93.3% had a general anaesthetic.
Mastectomy (M) was performed in 51.6%, M following a wide local excision
(WLE) in 4.2% and WLE in 44.2%. Axillary surgery (n¼93) was either an
axillary sampling (AS) in 5%, AS and clearance (AC) in 1%, primaryAC in87.1%,
sentinel node biopsy (SNB) in 3.2% and SNB followed by AC in 3.2% (3 of 93).
30 day mortality was 0.008% (1 of 120) following a myocardial infarction. 10
patients had minor complications. Median follow up (SC) was 24 months
versus 20 months (C). Overall survival was 89%(SC) versus 50% (C).
Conclusion: Elderly patients with breast cancer, can be treated surgically
with an intent to cure, safely and this has an impact on survival.
0470: A RETROSPECTIVE ANALYSIS OF PHYLLODES TUMOURS AND B3
LESIONS ON CORE BIOPSY
Lucinda Frank, Sarah Vestey, Richard Bryan. Gloucester Royal Hospital,
Gloucester, UK.
Aim: To determine the accuracy of core biopsies in diagnosing Phyllodes
tumours.
Method: A retrospective analysis of all cases of Phyllodes tumours on
excision biopsy was undertaken from March 2006 e July 2012. This was
then cross-referenced with all B3 lesions on core biopsy for the same time
period.
Results: 59 cases of Phyllodes tumour were identiﬁed in Gloucester and
Cheltenham NHS trust. These cases were classiﬁed as B2, B3 and B4 on core
biopsy. 15% Phyllodes tumours were classiﬁed as ﬁbroadenomas on core
biopsy. 69% cases were classiﬁed as B3. 48/392 B3 core biopsies in the same
time period raised the possibility of a Phyllodes tumour, 33 of these were
conﬁrmed as Phyllodes tumours on excision.
Conclusion: A high index of suspicion of Phyllodes tumours is important
when analysing core biopsies as this will dictate whether cavity shaves are
taken at the time of excision. A signiﬁcant number of patients had Phyl-
lodes tumours diagnosed on excision biopsy following a B2 core biopsy,
this highlights a need to educate patients about the risk of Phyllodes tu-
mours if their breast lump increases in size or changes as Phyllodes tu-
mours represent an ongoing diagnostic challenge.
0495: PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN
AN IRISH POPULATION OF PATIENTS WITH BREAST CANCER
Eamon Francis, Aoife Lowery, Ruth Prichard, James Geraghty, Denis Evoy,
Enda Mc Dermott. St Vincents University Hospital, Dublin 4, Ireland.
Aims: This study aimed to determine the rate of complete pathological
response (pCR) following neoadjuvant chemotherapy and identify clinico-
pathologic factors, with speciﬁc reference to Her2 status, associated with a
pCR. It assessed the validity and applicability of the MD Anderson nomo-
gram to predict response to neoadjuvant chemotherapy.
Methods: Ninety patients who received neoadjuvant chemotherapy
within a ﬁve year period were identiﬁed. Patient demographics, patho-
logical tumour characteristics were recorded. The probability of a pCR was
calculated using the Neo!adjuvant nomogram to etermine its accuracy in
an Irish population.
Results: Eighty-seven patients were included in the ﬁnal analysis. Overall,
13.79% (n¼12) of patients had a pCR. All tumours exhibiting a pCR were
invasive ductal carcinomas. The absence of LVI was statistically signiﬁcant
in predicting pCR (p¼ <0.05). Oestrogen receptor (ER) positivity and HER2
positivity were also signiﬁcantly associated with a pCR (p¼ <0.05). The
application of the MD Anderson Neo!adjuvant nomogram to our Irish
cohort of patients with breast cancer was validated with an area under the
curve (AUC) of 0.722.
Conclusion: pCR is associated with invasive ductal carcinoma, the absence
of lymphovascular invasion, oestrogen negativity and Her2 receptor pos-
itivity. The Neo!adjuvant nomogram for women undergoing neoadjuvant
chemotherapy was validated.
0499: BLUE DYE IN SENTINEL LYMPH NODE BIOPSY FOR BREAST CAN-
CER. ARE WE FOLLOWING THE GUIDELINES?
Sudin Daniel, Abraham Mathew, Ali Nejim. Airedale General Hospital,
Keighley, West Yorkshire, UK.
Abstracts / International Journal of Surgery 11 (2013) 589e685606
ABSTRACTSIntroduction: Patent Blue V dye is routinely used in the UK for Sentinel
Lymph node biopsy. However, it causes allergic reactions in (0.6-2.7%). The
NEWSTART and ALMANAC studies have reported 1% incidence. The ABS
guidelines 2009, recommends routine consenting for blue dye adminis-
tration and allergic reactions.
Materials and Methods: We looked into 41 cases of WLE/Mastectomy
with SLNB done over a 3 month period. All patients had 2ml of 2.5% PBV
injected subareolarly.
Results: 50% were consented for administration, and only 50% had allergic
responses mentioned. One patient had allergic reaction to blue dye man-
ifesting as intaoperative hypotension requiring ephedrine. There were no
delayed effects. Urticarial rashes, blue hives were seen in 3 patients but
were self-limiting. A similar audit done at a regional tertiary centre, the
consenting rates where 65% despite using pre-printed consent forms
because pre-printed consent forms were not used in all patients.
Conclusion: Patent Blue dye injection is not without risks and therefore
PBV administration and allergic responses to patent blue dye should
routinely be mentioned in consent forms. Using pre-printed forms can
improve the consenting rates, but it requires more awareness and persu-
ation among doctors.0563: THE USE OF CHEST X-RAYS AS A ROUTINE STAGING INVESTIGA-
TION FOR PATIENTS WITH INVASIVE BREAST CANCER e AN AUDIT OF
CURRENT PRACTICE
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2Highland Breast Centre, NHS Highland, Highland, UK.
Aim: We investigated whether patients diagnosed with invasive breast
cancer in NHS Highland received a CXR in line with local preoperative
assessment guidelines.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed if patients received a
pre-operative CXR.
Performing CXRs in 95% was deemed an acceptable audit standard.
Abnormal CXRs were identiﬁed and investigated in more detail.
Results: 111 Patients were diagnosed with invasive breast cancer.
Of the 98 patients who had surgery, 87 had a CXR (89%). Audit standard
failed.
68 CXRs were normal, although metastastic disease was subsequently
identiﬁed in 1 patient. 19 CXRs were abnormal, with 7 CXRs thought to be
due to a metastatic cause.
0 metastases were found in these patients on other imaging modalities.
Conclusions: Routine preoperative CXRs were not being performed in
accordance with local guidelines. Published national guidelines suggest
CXRs are not indicated in asymptomatic patients with invasive breast
cancer and clearly are not an effective tool in our population. Completing
the audit loop was thought unhelpful as this local data has changed
practice and helped suggest a more effective staging strategy.0565: CT OR NOT CT? HOW SHOULD WE LOOK FOR DISTANT METASTA-
SES IN INVASIVE BREAST CANCER IN NHS HIGHLAND?
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2 The Highland Breast Centre, NHS Highland, Highland, UK.
Aim: Invasive breast cancer can metastasize to distant organs. SIGN(1)
Guidelines (84) suggest that no staging is required for T1-2 N0-1 tumours
in asymptomatic women. We aimed to identify an effective strategy for
staging investigations in NHS Highland.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed staging in-
vestigations performed and the presence of conﬁrmed metastases.
Results: 111 patients were diagnosed with invasive breast cancer. 98 had
surgery. 5 were identiﬁed with asymptomatic metastases in the pre/peri-
operative period. 87 CXR were performed. 19 were abnormal. 0 metastases
identiﬁed 28 nucleotide bone scans. 9 abnormal. 2 metastases. 22 Liver USS.
4 abnormal. 0 metastases. 20 CT scans.13 abnormal. 3 metastases.
Conclusions: A low proportion of patients with metastases were identi-
ﬁed. CT chest/abdomen/pelvis is now used as the primary staging inves-
tigation for asymptomatic metastases in patients with preoperative
clinically bulky nodes, 4 nodes positive on post-operative histology and inpatients considered for reconstruction. Correlation with other screening
modalities is used if results are equivocal.
References
(1) SIGN 84 Management of Breast Cancer in Women: A National Clinical
Guideline. December 20050576: MALE BREAST CANCER AND THE ROLE OF GENETIC TESTING:
SHOULD WE INTRODUCE SIMBA (SCREENING IN MALE BREAST
CANCER)?
Simba. Mersey Research Group for Surgery (MeRGS), Mersey, UK.
Aims: To evaluate incidence of male breast cancer in Merseyside, assess
the proportion of BRCA2 carriers and explore if there is a beneﬁt of known
male gene carriers being offered screening.
Method:Retrospective cohort studyof5 centres inMerseyside reviewingmale
patients with breast cancer identiﬁed between 01/01/2000 and 31/10/2012.
Data collected on family history, BRCA gene testing, histology and treatment.
Results: Forty-ﬁve patients identiﬁed; median age 70years (range 37-93).
All presented with a breast lump. Fourty-one(91%) underwent mastec-
tomy; 36(80%) had grade 2/3 disease; 100% were ER+. Fifteen(33%) had
involved lymph-nodes and 10(22%) had lymphovascular invasion. All pa-
tients had anti-endocrine therapy, 6(13%) also underwent chemotherapy.
Six(13%) had family history of breast cancer, 5(11%) had BRCA testing, with
only one(2%) having a BRCA2mutation. The 5 year survial ratewas 62%(16/
26). 36%(4/11) of recorded deaths were related to breast cancer.
Conclusions: Incidence of male breast cancer in Merseyside appears lower
than national average. Findings suggest men have higher grade, ER+ tu-
mours and are likely to undergo mastectomy. Only a small proportion
underwent BRCA testing, raising the question should we be testing all male
breast cancers? Further work is ongoing evaluating BRCA2 rate in Mer-
seyside, in conjunction with Clinical Genetics.0596: ASIT-MAMMARY FOLD PRIZE WINNER: CYTOKERATIN-19 (CK19)
NEGATIVE BREAST CANCERS AND ONE-STEP NUCLEIC ACID AMPLIFICA-
TION (OSNA): MUCH ADO ABOUT NOTHING?
Dionysios-Dennis Remoundos 1, Meera Joshi 1, Farid Ahmed1, Yoon Chia 2,
Giles Cunnick 1,2. 1Department of Breast Surgery, Wycombe Hospital, High
Wycombe, UK; 2Department of Pathology, Wycombe Hospital, High Wycombe, UK.
Background: Sentinel Node Biopsy is standard practice for staging the axilla,
with OSNA more widely used in clinical practice. Nearly all breast cancers
express CK19, andOSNAdetects nodalmetastasis by quantifying the levels of
CK19 mRNA. Limited data exists on the true incidence of CK19-negative tu-
mours. Hence, we investigated the expression of CK19 in our practice.
Methods: All new breast cancer patients in a single centre between May
2010 and May 2012 were identiﬁed retrospectively. The tumour details,
including CK19 status, were retrieved from the pathology reports.
Results: 730 breast cancer patients were identiﬁed. 104 were excluded due
to incomplete data or lack of CK19 immunohistochemical (IHC) staining.
Details from 626 patients were analysed. 16 tumours were CK19-negative
(2.6%). The CK19 status was independent of the tumour histological and
hormone proﬁles. The median age of CK19-negative patients was older
than CK19-positive patients (76 vs 62 respectively).
Conclusions: This is one of the largest series looking at CK19-negative
tumours. As they are rare, routine testing prior to OSNA may not be
necessary. However, the exact correlation between CK19 expression by IHC
and the OSNA results remains uncertain. Studies investigating the pres-
ence or absence of CK19 mRNA may be more appropriate.0655: VTE PROPHYLAXIS FOR BREAST SURGERY; A PROSPECTIVE AUDIT
Miriam Thake, Sheila Shokuhi, Monika Kaushik. Department of Breast and
Oncoplastic Surgery, Glenﬁeld Hospital, University Hospitals of Leicester,
Leicester, UK.
Introduction: Each year approximately 25,000 people die from veno-
thrombolic events, 25 times the number that die from MRSA infection.
There is no consensus in the timing and dose of prophylactic LMWH in
patients undergoing breast surgery. The incidence of VTE in breast surgery
has been shown to be approximately 0.03%.
Aim: To compare the current practice of thromboprophylaxis for patients
undergoing breast surgery with the University Hospitals of Leicester (UHL)
protocol and NICE guidelines to standardise practice.
